Levosimendan Kalceks (Levosimendan)

Levosimendan works by binding to troponin C, making the heart muscle more responsive to calcium, which increases contractile force. At the same time, it opens ATP‑sensitive potassium channels in blood‑vessel walls, causing vasodilation and lowering the workload on the heart.

The dosage of Levosimendan Kalceks is determined by the prescribing clinician based on the patient’s condition, weight, and response. The prescriber sets the infusion rate and duration according to clinical guidelines and individual therapeutic needs.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, reducing the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that can be advantageous in certain heart‑failure scenarios.

Levosimendan Kalceks must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vials in their original packaging until use to maintain stability and potency.

Levosimendan Kalceks is given as an intravenous infusion. The solution is typically administered over a period of 24 hours, with continuous monitoring of blood pressure, heart rhythm, and clinical response throughout the infusion.

The most serious risks include severe hypotension, ventricular tachyarrhythmias, myocardial ischemia, and rare anaphylactic reactions. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after the infusion.

Levosimendan should be avoided in patients with known hypersensitivity to the drug, uncontrolled severe hypotension, or those receiving concurrent strong vasodilators that could precipitate dangerous blood‑pressure drops. Clinicians must assess each patient’s overall condition before initiating therapy.